EPIDIOLEX has a low potential for abuse2
- Demonstrated in a human abuse potential study at therapeutic doses and supratherapeutic doses
- CBD neither directly binds to nor activates CB1 and CB2 receptors at physiologically achievable concentrations
EPIDIOLEX is manufactured according to strict specifications
Learn how EPIDIOLEX is produced to ensure each bottle meets FDA quality standards.
EPIDIOLEX is held to high quality standards
|Established Efficacy, Safety, and Dosing|
Significant seizure reduction2
Well-characterized safety profile2
Get EPIDIOLEX information
References: 1. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. Food and Drug Administration website. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm611046.htm. Accessed June 29, 2018. 2. EPIDIOLEX [package insert]. Carlsbad, CA: Greenwich Biosciences, Inc.; 2018. 3. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147:S163-S171. 4. Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and epilepsy. Neurotherapeutics. 2015;12:747-768. 5. Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011-2020. 6. Devinsky O, Patel AD, Cross JH, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378:1888-1897. 7. Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018. doi:10.1016/S0140-6736(18)30136-3. 8. Ostendorf AP, Ng YT. Treatment-resistant Lennox-Gastaut syndrome: therapeutic trends, challenges and future directions. Neuropsychiatr Dis Treat. 2017;13:1131-1140. 9. Data on file. Greenwich Biosciences, Inc., Carlsbad, CA.